Atlas Trials

Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions

Clinical trial NCT02367027 · COMPLETED

Trial details

NCT number
NCT02367027
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Pharmacokinetics
Start date
2015-02-01
Primary completion
2015-04-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.